

February 20, 2025

#### **Chair Mike Jacobson**

Banking, Commerce and Insurance Committee Nebraska Legislature 1445 K St, Room 1507 Lincoln, NE 68509

## The Honorable Eliot Bostar

Banking, Commerce and Insurance Committee Nebraska Legislature 1445 K St, Room 1507 Lincoln, NE 68509

# The Honorable Brian Hardin

Banking, Commerce and Insurance Committee Nebraska Legislature 1445 K St, Room 1507 Lincoln, NE 68509

# The Honorable R. Brad von Gillern

Banking, Commerce and Insurance Committee Nebraska Legislature 1445 K St, Room 1507 Lincoln, NE 68509

#### Vice-Chair Bob Hallstrom

Banking, Commerce and Insurance Committee Nebraska Legislature 1445 K St, Room 1507 Lincoln, NE 68509

## The Honorable George Dungan

Banking, Commerce and Insurance Committee Nebraska Legislature 1445 K St, Room 1507 Lincoln, NE 68509

# The Honorable Merv Riepe

Banking, Commerce and Insurance Committee Nebraska Legislature 1445 K St, Room 1507 Lincoln, NE 68509

# The Honorable Dave Wordekemper

Banking, Commerce and Insurance Committee Nebraska Legislature 1445 K St, Room 1507 Lincoln, NE 68509

Dear Chair Jacobson and Members of the Nebraska Banking, Commerce and Insurance Committee,

Thank you for holding this hearing on critical legislation that will benefit individuals across Nebraska. I am writing in strong support of Nebraska Legislature Bill 252 and urge its swift passage to help prevent opioid addiction in the state. Voices for Non-Opioid Choices ("Voices") applauds Senator Eliot Bostar for introducing LB 252, which takes important steps to reduce opioid addiction by expanding access to non-opioid pain management options. We fully support this legislation and its efforts to ensure Nebraskans have safer alternatives for pain treatment.

For too long, our response to the opioid addiction crisis focused solely on opioid overdose death prevention. Such a focus misses the opportunity to prevent addiction where we can, including by reducing and minimizing unnecessary exposure to opioids. One opportunity to do this is to increase the availability of non-opioid pain management approaches. In doing so, LB 252 will prevent opioid addiction for many Nebraskans and save lives.

Voices for Non-Opioid Choices (<u>www.nonopioidchoices.org</u>) is a national, non-partisan, and nonprofit organization based in Washington, DC dedicated to preventing opioid addiction. Our coalition boasts over 20,000 advocates and 200 member organizations from across the country representing the leading patient, provider, and public health advocacy organizations. All told, Voices' members represent millions of Americans affected by the U.S. opioid epidemic.

Despite years of attention to combatting the opioid epidemic, the crisis persists. Last year, we lost 81,000 Americans to an opioid-related drug overdose.<sup>i</sup> This means that, on average, <u>we lose</u> more than 200 Americans every day to an opioid-related drug overdose.

Nebraska is not immune from this national epidemic. In 2023, there were <u>74 opioid-related</u> <u>overdose deaths</u>, accounting for <u>55.6% of all drug overdose fatalities</u> in the state.<sup>ii</sup> For many, the path towards addiction begins after being prescribed opioids to manage an acute pain incident, such as for postsurgical pain, an accident, or sports injury. In Nebraska, there were <u>42.7 opioid prescriptions written for every 100 persons</u> in 2023.<sup>iii</sup>

Fortunately, this is a path to addiction that can be prevented by ensuring access to non-opioid approaches.

Prescription opioids are frequently used to treat acute pain. In fact, as many as <u>90 percent of all</u> <u>surgical patients</u> in the United States receive a prescription for opioids to manage postsurgical pain.<sup>iv</sup> It is easy to understand why prescription opioids are frequently used – medical professionals are trained to treat pain with opioids, they are seen as effective ways to treat pain, and, perhaps most importantly, generic prescription opioids are incredibly cheap. As such, health insurers frequently make generic opioids available to patients at little – or no – charge to the patient.

# <u>This inadvertently incentivizes patients – and their healthcare providers – to treat pain with</u> <u>prescription opioids. We must change this care paradigm.</u>

LB 252 prohibits stricter coverage restrictions, higher cost-sharing, or formulary disadvantages for non-opioids compared to opioids, mandating immediate coverage for newly FDA-approved non-opioid drugs.

LB 252 would not put prescription opioids out-of-reach for those patients who want – or require – those treatments. Rather, the legislation would ensure that Nebraskans would have full access to the full suite of safe, effective, and FDA-approved pain management approaches, including both opioid and non-opioid options.

The legislation being considered today mirrors a federal bill, the Alternatives to Prevent Addiction in the Nation (Alternatives to PAIN) Act, which was recently reintroduced in the 119<sup>th</sup> Congress. <u>Simply put, we must ensure that all patients can easily access non-opioid pain</u> <u>approaches across all care settings.</u>

Voices for Non-Opioid Choices urges the federal and state government to continue to work hand-in-hand to solve the opioid crisis currently taking place in Nebraska, and throughout the country. For too long, prescription opioids have been the default method for managing pain – and insurance company practices have reinforced this reality. This puts patients at unnecessary risk for misuse and addiction.

Voices applauds the advancements proposed in LB 252. This bill would enable more patients to have access to non-addictive products and would improve care for the tens of thousands of Nebraskans who experience an acute pain incident every year.

Once again, thank you for making the time today to recognize and examine the importance of expanding access to non-addictive opioid alternatives throughout Nebraska. I urge the committee to take action to prevent opioid addiction before it starts and pass LB 252.

Thank you for your consideration of these comments. I stand ready to work with your committee and the full delegation to prevent opioid addiction and enact this important legislation. Should you have any questions, please feel free to contact me at <a href="https://chris@nonopioidchoices.org">chris@nonopioidchoices.org</a>.

With appreciation,

Chris Fox Executive Director Voices for Non-Opioid Choices

<sup>III</sup> Center for Disease Control and Prevention (2024). Opioid Dispensing Rate Maps.

<sup>&</sup>lt;sup>i</sup> Centers for Disease Control and Prevention (2024).US Overdose Deaths Decrease in 2023, First Time Since 2018. <u>https://www.cdc.gov/nchs/pressroom/nchs\_press\_releases/2024/20240515.htm</u>

<sup>&</sup>lt;sup>ii</sup> Centers for Disease Control and Prevention (2024). SUDORS Dashboard: Fatal Drug Overdose Data. https://www.cdc.gov/overdose-prevention/data-research/facts-stats/sudors-dashboard-fatal-overdosedata.html

https://www.cdc.gov/overdose-prevention/data-research/facts-stats/opioid-dispensing-rate-maps.html

<sup>&</sup>lt;sup>iv</sup> Singh, K., Murali, A., Stevens, H., Vydiswaran, V. G. V., Bohnert, A., Brummett, C. M., & Fernandez, A. C. (2022). Predicting persistent opioid use after surgery using electronic health record and patient-reported data. Surgery, 172(1), 241–248. <u>https://doi.org/10.1016/j.surg.2022.01.008</u>